Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1650664 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD)
Last $2.69Day +3.46%Mkt cap $263M1Y +6.7%Off 52W high −40.7%Vol (1Y) 90.8%
Split-adj closes · 240 of 2,635 · price rtn
| Short interest22.7% of sh out |
| Days to cover8.0d |
| 13F net flow (QoQ)+0.13% |
| Top-10 13F concentration66.6% |
| Next report (est.)2026-08-04 |
SI 2026-07-15 · 13F 2026-Q1
| Sales (TTM)$38.7M |
| Earnings (TTM)-$109.0M |
| ROE−198.1% |
| Net margin−395.0% |
| Debt / equity2.15× |
| Sales growth 3Y27.1% |
FY ratios · TTM sales/earnings (USD)
| YTD+31.2% |
| 1Y+6.7% |
| 3Y−69.4% |
| 5Y−93.6% |
| 10Y−89.5% |
| Since incept. (ann.)−16.7% |
Total return · from 2016-02-03
| Ann. volatility (1Y)90.8% |
| Ann. volatility (3Y)101.7% |
| Sharpe (1Y)0.48 |
| Sharpe (3Y)0.08 |
| Max drawdown (1Y)−59.9% |
| Max drawdown (3Y)−91.2% |
| Beta (3Y vs SPY)2.75 |
Daily returns, ann.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 9.3M | $23M | 9.46% | −0.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2M | $10M | 4.30% | new |
| RENAISSANCE TECHNOLOGIES LLC | 4.0M | $10M | 4.06% | +30.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.1M | $8M | 3.22% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3M | $6M | 2.36% | +1.2% |
| STATE STREET CORP | 2.1M | $5M | 2.12% | +5.1% |
| Nuveen, LLC | 2.0M | $5M | 2.02% | +0.0% |
| D. E. Shaw & Co., Inc. | 1.9M | $5M | 1.99% | +75.2% |
Δ vs 2025-Q4
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$0.26 | — | $2.8M | −39.2% |
| 2025-12-31 | 2026-03-09 | — | — | $24.7M | −19.2% |
| 2025-09-30 | 2025-11-10 | −$0.28 | — | $7.5M | +12265.6% |
| 2025-06-30 | 2025-08-12 | −$0.63 | — | $3.6M | +597.5% |
As-reported XBRL · next 2026-08-04 est.
Reportable 100%
business · TAGGED revenue
